President Donald Trump’s promise to impose tariffs on pharmaceutical imports is raising red flags among generic drugmakers and industry experts, who warn that such a move could lead to increased drug ...

The president said he would build on the Medicare drug-price negotiation program begun under Joe Biden, but supports a change ...

President Trump directed his administration to help states import drugs from Canada. But a proposal to alter a Medicare ...

Celltrion Inc., a major South Korean biopharmaceutical firm, said Monday it has obtained an interchangeability approval for ...

As Fierce Pharma points out, patent expirations are a routine occurrence in the pharmaceutical world, but 2025 stands out for ...

JC Scott, CEO and president of The Pharmaceutical Care Management Association, discusses current efforts in increasing biosimilar adoption and pharmacy benefit manager (PBM) reform.

Leading pharmacy benefit managers are shifting away from lucrative rebates on biologic drugs and toward lower-cost biosimilar ...

With so many Mainers struggling to make ends meet, we cannot allow this well-intentioned but misguided legislation to become ...

Expiring patents can be a catalyst for M&A in the life sciences industry as pharmaceutical and biotechnology companies seek ...

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...